Also known as: Lupin
Lupin Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It focuses heavily on generic medicines across multiple therapeutic areas and serves multiple international markets.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Lupin has signed a license and supply agreement with Spektus Pharma to commercialize DeslaFlex, a novel antidepressant for Major Depressive Disorder, in Canada, strengthening its CNS portfolio.
Lupin Limited reported strong Q3 FY26 results with total sales of ₹71,005 million, up 26% year-over-year, and received US FDA approval for its pegfilgrastim biosimilar Armlupeg™, which has not yet been launched.
Dr Reddy's and Biocon plan to launch generic versions of Novo Nordisk's weight-loss drugs at up to 60% below branded prices as semaglutide patents expire, targeting a global market projected to reach $150 billion by the early 2030s.
Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00958633 |
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. |
TERMINATED | PHASE3 |
